California-based biotechnology company Glycomine, Inc. has completed with $33 million in a Series B round of funding led by Danish life science investor Novo Holdings A/S.

The funding round also had participation from new backers, Asahi Kasei Pharma Corp. and Mission Bay Capital, and existing investors, Sanderling and Chiesi Ventures.

Glycomine will use the money raised from the funding round to advance its substrate replacement therapy for PMM2-CDG (CDG-1a) into early-stage clinical studies.

The company, with about $1 million in revenue annually, has raised a total of $45 million in over two funding rounds.